The Treatment That Prescribes the Drug
Of all the interventions this series has documented, heroin-assisted treatment carries the heaviest rhetorical weight: the supervised prescription of pharmaceutical-grade heroin (diamorphine) to people with severe, treatment-refractory opioid dependence, as the treatment itself, in the clinics where the doses are administered under medical supervision. The intervention is the safe-supply post's most complete form (not the replacement of the unknown supply with a regulated one in principle, but in full practice: the drug itself, prescribed, dosed, supervised, indefinitely where the alternative is the street's contamination and the addiction's mortality), and it carries the drug war's ultimate taboo (the state as the provider of the prohibited drug, the treatment that does not demand the abstinence but manages the dependence) and the evidence to vindicate it (the Swiss and the Dutch and the German and the Canadian trials that the policy's opponents have never refuted). This post is the heroin-assisted treatment account: the Swiss model's development, the trial evidence, the outcomes, and the question it poses to the rest of the world.
The Swiss Model's Development
The development deserves the historical context, because the Swiss program was the crisis's answer. Switzerland of the late 1980s and the early 1990s (the open drug scenes of the Platzspitz in Zurich and the similar across the cities, the visible concentrations of the heroin-dependent population, the HIV's transmission through the scenes, the public-order crisis that the scenes' visibility produced, the policy crisis that the scenes' persistence forced) faced the overdose and the infection epidemics that the criminalization was not containing, and the policy response that emerged (the four-pillars strategy: prevention, treatment, harm reduction, and enforcement, the pillars' integration being the innovation) included the radical pillar's experiment: the heroin-assisted treatment trials (the 1994 onset, the rigorous evaluation mandate that the skeptical Parliament attached, the expectation that the trials would fail and could then be abandoned). The trials did not fail. The outcomes (the treatment-retention rates exceeding every alternative, the illegal-heroin-use's collapse among the participants, the health and the crime outcomes that the evaluation documented) converted the experiment into the permanent program (the national rollout, the clinics' network, the decades of operation), and the Swiss model became the international demonstration that the taboo's violation worked.
The Evidence
The evidence deserves the systematic statement, because it has accumulated across the jurisdictions. The Swiss trials and the follow-ups (the retention in treatment at the rates the methadone programs never achieved for this population, the illegal-drug-use reductions, the thefts and the drug-crime's collapse, the physical and the mental health improvements, the mortality outcomes), the Dutch and the German and the British trials (the randomized evidence that the RCTs' gold-standard added, the diamorphine-versus-methadone comparisons finding the heroin-assistance superior for the refractory population the trials enrolled), and the Canadian NAOMI and the SALOME trials (the North American replications, the prescription-heroin's outcomes confirming the European findings) are the core, and the outcomes' pattern deserves the summary: for the severe, refractory, street-heroin-dependent population (the users failed by every other treatment, the highest-mortality and the highest-cost population in the system), the prescription of the supervised pharmaceutical heroin achieves the outcomes that no other intervention achieves (the retention, the street-use's cessation, the crime's collapse, the health's stabilization, the mortality's reduction), at the cost of a program that the rest of the system finds politically indigestible.
The Outcomes, Specified
The outcomes deserve the specification, because the generalities undersell them. The illegal-use reductions (the participants' street-heroin consumption collapsing to the fractions, the supply-demand's interruption that the prescription produces), the crime reductions (the acquisitive crime's collapse, the participants no longer funding the street habit, the property-crime statistics' improvement in the program evaluations), the health outcomes (the HIV and the hepatitis transmission's interruption within the supervised model, the injection-injuries' reduction, the physical-health's stabilization), the social outcomes (the housing and the employment improvements, the participants' reconnection to the ordinary life, the series' social-determinants integration at its most direct), the mortality (the overdose deaths' reduction, the pharmaceutical-dose's predictability against the street's contamination, the series' fentanyl-era arithmetic's cleanest answer), and the system's costs (the program expensive per-participant and cost-saving at the population level against the crime and the health and the incarceration costs the refractory population otherwise generates). The honest limitations deserve the same breath (the population's restriction to the refractory-severe, the clinic-model's supervision requirement that the take-home models relax at the risk-profile's cost, the political sustainability's dependence on the scenes'-crisis memory that the success erodes).
The Resistance and the Question
The resistance deserves the honest anatomy, because it is the series' recurring dynamic at the policy's most extreme. The moral objection (the state-as-provider framing, the abstinence-ideal's violation, the same deservingness-logic the Housing First post anatomized, the taboo's protection by the framing that the prescription is the surrender rather than the treatment), the policy objection (the diversion risk that the supervised model's design minimizes and never eliminates, the message that the prescription sends in the prohibitionist's framing), and the pragmatic objection (the cost, the complexity, the political capital) are the arguments, and the evidence's reply is the series' constant (the outcomes refute the predicted harms, the diversion's rarity, the populations' restriction to the failed-by-everything, the cost's offset). The question the Swiss model poses deserves the closing statement: if the supervised prescription of the prohibited drug itself, the taboo's ultimate violation, produces the outcomes the evidence documents (the retention, the street's collapse, the mortality's reduction), then the taboo's remaining justifications are the ideology's alone, and the rest of the world's abstinence from the model is the measure of the distance between the evidence and the politics that this series, across a hundred and seventy-two posts, has been measuring from the first.
The Bottom Line
Heroin-assisted treatment is the harm reduction principle's furthest reach and its most complete vindication: the supervised prescription of the drug itself, to the population failed by everything else, producing the outcomes (the retention, the street-use's collapse, the crime's collapse, the mortality's reduction) that the ideology predicted it could not, in the Swiss clinics that the skeptical Parliament authorized expecting failure and made permanent on the evidence. The program is not for everyone (the refractory-severe restriction is the design's prudence), it is not cheap (and is cost-saving against the alternatives), and it is not politically easy (the taboo's weight is real, and the resistance recycles the tested-and-failed arguments). But for the population it serves, it is the difference between the street's contamination and the clinic's supervision, between the fentanyl's lottery and the pharmaceutical's predictability, between the death the series has documented by the hundreds of thousands and the life the program has prolonged by the decades. The Swiss answered the overdose crisis with the prescription. The evidence vindicated them. The rest of the world is still deciding whether the taboo is worth the bodies.
